Direct and indirect neurological manifestations of COVID-19
OBJECTIVE: To systemize the neurological manifestations of COVID-19.
MATERIALS AND METHODS: A systematic computer analysis of all currently available publications on the neurological manifestations of COVID-19 (2374 publications in PUBMED) using algorithms of topological data analysis was performed.
RESULTS: A complex of interactions between SARS-CoV-2 infection, metabolic disorders of neurotransmitters (acetylcholine, dopamine, serotonin and GABA), enkephalins and neurotrophins, micronutrients, chronic and acute inflammation, encephalopathy, cerebral ischemia and neurodegeneration, including demyelination, was described. The most common neurological manifestation of COVID-19 is anosmia/ageusia arising as a result of ischemia, neurodegeneration, and/or systemic elevation of proinflammatory cytokine levels. COVID-19 provokes ischemic stroke, Guillain-Barré syndrome, polyneuropathy, encephalitis, meningitis and parkinsonism. Coronavirus infection significantly aggravates the course of multiple sclerosis and myopathies. Possible roles of the human virome in the neuropathophysiology of COVID-19 are considered. A case of clinical management of a patient with neurological complications of COVID-19 is described.
CONCLUSION: In the long term, COVID-19 stimulates neurodegenerative changes, which require specific programs of neurological rehabilitation. It is advisable to use choline drugs and antihypoxants that are compatible with COVID-19 therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:120 |
|---|---|
| Enthalten in: |
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova - 120(2020), 11 vom: 07., Seite 11-21 |
| Sprache: |
Russisch |
|---|
| Weiterer Titel: |
O pryamykh i kosvennykh nevrologicheskikh proyavleniyakh COVID-19 |
|---|
| Beteiligte Personen: |
Gromova, O A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 22.12.2020 Date Revised 22.12.2020 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.17116/jnevro202012011111 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM31905151X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM31905151X | ||
| 003 | DE-627 | ||
| 005 | 20231225170634.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||rus c | ||
| 024 | 7 | |a 10.17116/jnevro202012011111 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1063.xml |
| 035 | |a (DE-627)NLM31905151X | ||
| 035 | |a (NLM)33340292 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 100 | 1 | |a Gromova, O A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Direct and indirect neurological manifestations of COVID-19 |
| 246 | 3 | 3 | |a O pryamykh i kosvennykh nevrologicheskikh proyavleniyakh COVID-19 |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.12.2020 | ||
| 500 | |a Date Revised 22.12.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVE: To systemize the neurological manifestations of COVID-19 | ||
| 520 | |a MATERIALS AND METHODS: A systematic computer analysis of all currently available publications on the neurological manifestations of COVID-19 (2374 publications in PUBMED) using algorithms of topological data analysis was performed | ||
| 520 | |a RESULTS: A complex of interactions between SARS-CoV-2 infection, metabolic disorders of neurotransmitters (acetylcholine, dopamine, serotonin and GABA), enkephalins and neurotrophins, micronutrients, chronic and acute inflammation, encephalopathy, cerebral ischemia and neurodegeneration, including demyelination, was described. The most common neurological manifestation of COVID-19 is anosmia/ageusia arising as a result of ischemia, neurodegeneration, and/or systemic elevation of proinflammatory cytokine levels. COVID-19 provokes ischemic stroke, Guillain-Barré syndrome, polyneuropathy, encephalitis, meningitis and parkinsonism. Coronavirus infection significantly aggravates the course of multiple sclerosis and myopathies. Possible roles of the human virome in the neuropathophysiology of COVID-19 are considered. A case of clinical management of a patient with neurological complications of COVID-19 is described | ||
| 520 | |a CONCLUSION: In the long term, COVID-19 stimulates neurodegenerative changes, which require specific programs of neurological rehabilitation. It is advisable to use choline drugs and antihypoxants that are compatible with COVID-19 therapy | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a choline drugs | |
| 650 | 4 | |a complications | |
| 650 | 4 | |a neurological symptoms | |
| 700 | 1 | |a Torshin, I Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Semenov, V A |e verfasserin |4 aut | |
| 700 | 1 | |a Putilina, M V |e verfasserin |4 aut | |
| 700 | 1 | |a Chuchalin, A G |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova |d 1997 |g 120(2020), 11 vom: 07., Seite 11-21 |w (DE-627)NLM074605267 |x 1997-7298 |7 nnns |
| 773 | 1 | 8 | |g volume:120 |g year:2020 |g number:11 |g day:07 |g pages:11-21 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.17116/jnevro202012011111 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 120 |j 2020 |e 11 |b 07 |h 11-21 | ||